Curis Inc Q1 2025 Earnings Call Highlights Financial Improvements and Strategic Developments
| CRIS Stock | USD 1.60 0.03 1.84% |
Slightly above 62% of Curis' investor base is looking to short. The analysis of overall sentiment of trading Curis Inc stock suggests that many investors are alarmed at this time. Curis' investing sentiment can be driven by a variety of factors including economic data, Curis' earnings reports, geopolitical events, and overall market trends.
Net Loss 10.6 million or 1.25 per share for Q1 2025, compared to 11.9 million or 2.05 per share for Q1 2024.Research and Development Expenses 8.5 millio
Read at gurufocus.com
 |
Curis Fundamental Analysis
We analyze Curis' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Curis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Curis based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Asset
Current Asset Comparative Analysis
Curis is currently under evaluation in current asset category among its peers. Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Curis Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Curis stock to make a market-neutral strategy. Peer analysis of Curis could also be used in its relative valuation, which is a method of valuing Curis by comparing valuation metrics with similar companies.
Peers
Curis Related Equities
| LXRX | Lexicon Pharmaceuticals | 4.67 | ||||
| RIGL | Rigel Pharmaceuticals | 1.72 | ||||
| MREO | Mereo BioPharma | 0.60 | ||||
| CRVS | Corvus Pharmaceuticals | 0.70 | ||||
| AGEN | Agenus | 2.04 | ||||
| SLRX | Salarius Pharmaceuticals | 3.17 |
Additional Tools for Curis Stock Analysis
When running Curis' price analysis, check to measure Curis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curis is operating at the current time. Most of Curis' value examination focuses on studying past and present price action to predict the probability of Curis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curis' price. Additionally, you may evaluate how the addition of Curis to your portfolios can decrease your overall portfolio volatility.